Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 19;15(20):1862-1874.
doi: 10.1002/cmdc.202000419. Epub 2020 Sep 10.

The Critical Role of Passive Permeability in Designing Successful Drugs

Affiliations
Review

The Critical Role of Passive Permeability in Designing Successful Drugs

Li Di et al. ChemMedChem. .

Abstract

Passive permeability is a key property in drug disposition and delivery. It is critical for gastrointestinal absorption, brain penetration, renal reabsorption, defining clearance mechanisms and drug-drug interactions. Passive diffusion rate is translatable across tissues and animal species, while the extent of absorption is dependent on drug properties, as well as in vivo physiology/pathophysiology. Design principles have been developed to guide medicinal chemistry to enhance absorption, which combine the balance of aqueous solubility, permeability and the sometimes unfavorable compound characteristic demanded by the target. Permeability assays have been implemented that enable rapid development of structure-permeability relationships for absorption improvement. Future advances in assay development to reduce nonspecific binding and improve mass balance will enable more accurately measurement of passive permeability. Design principles that integrate potency, selectivity, passive permeability and other ADMET properties facilitate rapid advancement of successful drug candidates to patients.

Keywords: P-gp; absorption; blood-brain barrier; metabolism; passive permeability; renal clearance.

PubMed Disclaimer

References

    1. L. Di, E. H. Kerns, Drug-Like Properties: Concepts, Structure Design and Methods, Elevier, London, UK, 2016.
    1. K. Sugano, M. Kansy, P. Artursson, A. Avdeef, S. Bendels, L. Di, G. F. Ecker, B. Faller, H. Fischer, G. Gerebtzoff, H. Lennernaes, F. Senner, Nat. Rev. Drug Discovery 2010, 9, 597-614.
    1. U. Fagerholm, D. Nilsson, L. Knutson, H. Lennernas, Acta Physiol. Scand. 1999, 165, 315-324.
    1. L. Di, E. H. Kerns, Blood-Brain Barrier in Drug Discovery, Wiley, New Jersey, 2014.
    1. D. A. Smith, M. Rowland, Drug Metab. Dispos. 2019, 47, 665-672.

Substances

LinkOut - more resources